| 신생혈관녹내장에서 Bevacizumab 유리체강내 주입술의 효과 |
|
김형찬 |
|
Department of Ophthalmology, Konkuk University School of Medicine, Seoul, |
| Effects of Intravitreal Bevacizumab Injection on Neovascular Glaucoma |
|
Hyung Chan Kim |
|
|
| Abstract |
Purpose
To evaluate the effects of intravitreal bevacizumab injection on neovascular glaucoma (NVG). Methods: Retrospective and non-comparative study was made of patients who received intravitreal bevacizumab injection (1.25 mg/0.05 cc) for NVG. Outcome measures included intraocular pressure (IOP), range of neovascularization of iris (NVI) at baseline, 1 week, 1 month, and 3 months follow-up. Results: Ten eyes were included and followed up for 4.4±0.9 months. Before injection, baseline mean IOP was 50.7±6.5 mmHg (36∼59 mmHg) which significantly decreased to 25.9±12.7 mmHg (15∼55 mmHg) at 1 week, and sustained to 30.3±12.5 mmHg (12∼50 mmHg) at 1 month (p=0.007, 0.008). However, in two cases mean IOP increased to the level of before injection. So finally Ahmed valve implantation was done. Among the rest of 8 cases, mean IOP of 4 cases at 3-month increased significantly compared to that at 1 month, resulting in no significant difference with basal level. Regression of NVI was observed in all cases within 1 week. In 8 eyes, NVI remained regressed until 3 months. Conclusions: Intravitreal bevacizumab injection has a transient effect on NVG. It may be considered as an adjuvant to more definitive treatment (pan-retinal photocoagulation or glaucoma shunt procedures) in NVG. (Korean J Optom Vis Sci 2011;10(1):43-50) |
| Key Words:
Bevacizumab, Intravitreal bevacizumab injection (IVB), Neovascular glaucoma (NVG) |
|
PDF Links
Download Citation
